Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies DOI Creative Commons

Cinzia Maschio,

Ruiqing Ni

Frontiers in Aging Neuroscience, Journal Year: 2022, Volume and Issue: 14

Published: April 22, 2022

The detection and staging of Alzheimer’s disease (AD) using non-invasive imaging biomarkers is substantial clinical importance. Positron emission tomography (PET) provides readouts to uncover molecular alterations in the brains AD patients with high sensitivity specificity. A variety amyloid-β (Aβ) tau PET tracers are already available for diagnosis AD, but there still a lack affinity selectivity inclusions primary tauopathies, such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) Pick’s (PiD). This review aims provide an overview existing Aβ their binding properties from silico , vitro vivo assessment. Imaging pathologic proteins vital diagnosis, monitoring potential therapeutic approaches AD. Off-target radiolabeled white matter or other neural structures one confounding factor when interpreting images. To improve eliminate off-target binding, second generation have been developed. conclude, we further outlook tauopathies pathological features tauopathies.

Language: Английский

Advances and considerations in AD tau-targeted immunotherapy DOI Creative Commons
Alice Bittar, Nemil Bhatt, Rakez Kayed

et al.

Neurobiology of Disease, Journal Year: 2019, Volume and Issue: 134, P. 104707 - 104707

Published: Dec. 10, 2019

The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the process. However, accumulating evidence from experimental clinical studies investigate early process point towards required role tau AD etiology. Importantly, a large number characterize plethora pathological forms protein onset propagation. Immunotherapy is one most approaches anticipated make difference field therapeutics. Tau -targeted immunotherapy new direction after failure amyloid beta (Aß)-targeted growing highlight Aß-independent It now well established alone will likely be insufficient as monotherapy. Therefore, this review discusses updates on tau-targeted studies, AD-relevant species, promising biomarkers prospect combination therapies surround propagation an efficient timely manner.

Language: Английский

Citations

85
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease DOI Creative Commons
Deborah O T Alawode, Amanda Heslegrave, Nicholas J. Ashton

et al.

Journal of Internal Medicine, Journal Year: 2021, Volume and Issue: 290(3), P. 583 - 601

Published: May 22, 2021

Alzheimer's disease (AD) is increasingly prevalent worldwide, and disease-modifying treatments may soon be at hand; hence, now, more than ever, there a need to develop techniques that allow earlier secure diagnosis. Current biomarker-based guidelines for AD diagnosis, which have replaced the historical symptom-based guidelines, rely heavily on neuroimaging cerebrospinal fluid (CSF) sampling. While these greatly improved diagnostic accuracy of pathophysiology, they are less practical application in primary care, population-based epidemiological settings, or where resources limited. In contrast, blood accessible cost-effective source biomarkers AD. this review paper, using recently proposed amyloid, tau neurodegeneration [AT(N)] criteria as framework towards biological definition AD, we discuss recent advances biofluid-based biomarkers, with particular emphasis those potential translated into blood-based biomarkers. We provide an overview research conducted both CSF draw conclusions show promise. Given evidence collated review, plasma neurofilament light chain (N) phosphorylated (p-tau; T) translation clinical practice. However, p-tau requires comparisons between its various epitopes before can made one most robustly differentiates from non-AD dementias. Plasma amyloid beta (A) would prove invaluable early screening modality, but it very precise tests robust pre-analytical protocols.

Language: Английский

Citations

77
Body Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview DOI Creative Commons

Adrian Bălașa,

Cristina Chircov, Alexandru Mihai Grumezescu

et al.

Biomedicines, Journal Year: 2020, Volume and Issue: 8(10), P. 421 - 421

Published: Oct. 15, 2020

Neurodegeneration is a highly complex process which associated with variety of molecular mechanisms related to ageing. Among neurodegenerative disorders, Alzheimer’s disease (AD) the most common, affecting more than 45 million individuals. The underlying involve amyloid plaques and neurofibrillary tangles (NFTs) deposition, will subsequently lead oxidative stress, chronic neuroinflammation, neuron dysfunction, neurodegeneration. current diagnosis methods are still limited in regard possibility accurate early detection diseases. Therefore, research has shifted towards identification novel biomarkers matrices as biomarker sources, beyond amyloid-β tau protein levels within cerebrospinal fluid (CSF), that could improve AD diagnosis. In this context, aim paper provide an overview both conventional for found body fluids, including CSF, blood, saliva, urine, tears, olfactory fluids.

Language: Английский

Citations

72
Biosensors for detection of Tau protein as an Alzheimer's disease marker DOI
Mehrdad Ameri, Zahra Shabaninejad, Ahmad Movahedpour

et al.

International Journal of Biological Macromolecules, Journal Year: 2020, Volume and Issue: 162, P. 1100 - 1108

Published: June 27, 2020

Language: Английский

Citations

71
Machine Learning for Diagnosis of AD and Prediction of MCI Progression From Brain MRI Using Brain Anatomical Analysis Using Diffeomorphic Deformation DOI Creative Commons
Ali Haidar Syaifullah, Akihiko Shiino, Hitoshi Kitahara

et al.

Frontiers in Neurology, Journal Year: 2021, Volume and Issue: 11

Published: Feb. 5, 2021

Background: With the growing momentum for adoption of machine learning (ML) in medical field, it is likely that reliance on ML imaging will become routine over next few years. We have developed a software named BAAD, which uses algorithms diagnosis Alzheimer's disease (AD) and prediction mild cognitive impairment (MCI) progression. Methods: constructed an algorithm by combining support vector (SVM) to classify voxel-based morphometry (VBM) reduce concerned variables. grouped progressive MCI AD as spectrum trained SVM according this classification. randomly selected half from total 1,314 subjects neuroimaging Initiative (ADNI) North America training, remaining were used validation fine-tune model hyperparameters. created two types SVMs, one based solely brain structure (SVMst), other both Mini-Mental State Examination score (SVMcog). compared performance with expert neuroradiologists, further evaluated test datasets involving 519, 592, 69, 128 Australian Imaging, Biomarker & Lifestyle Flagship Study Aging (AIBL), Japanese ADNI, Minimal Interval Resonance Imaging (MIDIAD) Open Access Series Studies (OASIS), respectively. Results: BAAD's SVMs outperformed radiologists structural magnetic resonance review. The accuracy was 57.5 70.0%, respectively, whereas, SVMst 90.5%. diagnostic SVMcog ranged 88.0 97.1% 92.5 100%, progression 83.0% 85.0% SVMcog. In classified SVMst, 87.1% Aβ positive AV-45 positron emission tomography. Similarly, among patients spectrum, 89.5% progressed AD. Conclusion: Our has shown high It radiologists, expected provide clinical practice.

Language: Английский

Citations

60
Neuroimmune contributions to Alzheimer’s disease: a focus on human data DOI Open Access
Verena Haage, Philip L. De Jager

Molecular Psychiatry, Journal Year: 2022, Volume and Issue: 27(8), P. 3164 - 3181

Published: June 6, 2022

Language: Английский

Citations

44
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease DOI

Shital Rani,

Sudhrita Basu Dhar,

Akhil Khajuria

et al.

Cellular and Molecular Neurobiology, Journal Year: 2023, Volume and Issue: 43(6), P. 2491 - 2523

Published: Feb. 27, 2023

Language: Английский

Citations

23
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease DOI Creative Commons
Jangampalli Adi Pradeepkiran,

Javaria Baig,

Md Ariful Islam

et al.

Aging and Disease, Journal Year: 2024, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2024

Alzheimer's disease (AD) is a age-related neurodegenerative and major public health concern both in Texas, US Worldwide. This mainly characterized by amyloid-beta (Aβ) phosphorylated Tau (p-Tau) accumulation the brains of patients with AD increasing evidence suggests that these are key biomarkers AD. Both Aβ p-tau can be detected through various imaging techniques (such as positron emission tomography, PET) cerebrospinal fluid (CSF) analysis. The presence individuals, who asymptomatic or have mild cognitive impairment indicate an increased risk developing future. Furthermore, combination often used for more accurate diagnosis prediction progression. Along being disease, it associated other chronic conditions such cardiovascular obesity, depression, diabetes because studies shown comorbid make people vulnerable to In first part this review, we discuss biofluid-based Aβ, p-Tau & plasma could alternative sensitive technique diagnose second part, underlying molecular mechanisms linked how they affect clinical care.

Language: Английский

Citations

15
Surface-functionalized SERS platform for deep learning-assisted diagnosis of Alzheimer's disease DOI
Minjoon Kim, Sejoon Huh, Hyung Joon Park

et al.

Biosensors and Bioelectronics, Journal Year: 2024, Volume and Issue: 251, P. 116128 - 116128

Published: Feb. 12, 2024

Language: Английский

Citations

11
The neutrophil-to-lymphocyte ratio in Alzheimer's disease: Current understanding and potential applications DOI
Ahmed Sayed, Eshak I. Bahbah, Serageldin Kamel

et al.

Journal of Neuroimmunology, Journal Year: 2020, Volume and Issue: 349, P. 577398 - 577398

Published: Sept. 18, 2020

Language: Английский

Citations

69